34 / 40
Treatment-Related Adverse Event Summary
Category, n (%)
N = 153
Any grade
147 (96%)
Grade 3-4
72 (47%)
Led to death
0
Led to discontinuation
50 (33%)
Ipilimumab only
13 (8%)
Pembrolizumab after completing ipilimumab
16 (10%)
Ipilimumab and pembrolizumab for same AE
16 (10%)
Ipilimumab for 1 AE, later pembrolizumab for a
second AE
5 (3%)
a
Considered regardless of attribution to treatment or immune relatedness by the investigator.
Data cutoff date: July 17, 2018.
LONG SMR 2018